FigureYa233genepair
FigureYa233genepair
Author(s)
: Xiaofan Lu
Date
: 2025-09-22
Academic Citation
If you use this code in your work or research, we kindly request that
you cite our publication:
Xiaofan Lu, et al. (2025). FigureYa: A Standardized Visualization
Framework for Enhancing Biomedical Data Interpretation and Research
Efficiency. iMetaMed.
https://doi.org/10.1002/imm3.70005
需求描述
想按照文中的方法构建基因对预后模型
Requirement Description
I want to construct a gene pair prognostic model according to the
method in this paper
出自
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-017-0666-z
from
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-017-0666-z
Fig. 1 Illustration of LncRIndiv method and work-flow of this study.
b The schematic diagram of
LncRIndiv method
. Take
lncRNA-A as an example to describe the LncRIndiv method. Circles with
different color represent different lncRNAs. The
blue and
purple
human shapes represent the samples
with or
without reversal lncRNA pairs in each line
, respectively. The
red and green
human shapes represent the samples are
determined as
with and without differential expression of
lncRNA-A
by the LncRIndiv method.
应用场景
【提出问题】DESeq等方法 detect differentially expressed genes (DEGs)
in
sub-groups of cancer samples
, considering the
high heterogeneity
of lncRNA expression among patients,
none have been used in detecting DE lncRNAs in individual
patients
.
【前提假设】作者以前的工作发现 the relative expression rankings of
genes (miRNAs) tend to be
highly stable in specific
normal
human tissues but
widely disturbed in the
corresponding cancer
tissues, and the reversal relationship of
rank between genes (miRNAs) expression level can be used to identify DE
genes (miRNAs) in individual patient. 这次用同样的方式来看DE lncRNAs in
individual patients
【解决方案】例文建立了一个方法LncRIndiv（detect DE lncRNAs in
individual
patients），即使用gene-pair进行预后模型构建的方法，也就是通过成对基因来进行预后建模。
例如A和B基因，A表达量 > B表达量设为1，A表达量 <
B表达量设为0。筛选出多对基因，都变成0和1的形式，进行预后模型构建。
本文档带你复现这一方法。
【优点】基于排序获得的模型具有平台独立性，只要单样本基因之间表达具有可比性就可以了。
…due to experimental batch effects and platform differences, the
score-based signatures
tend to produce spurious risk
classification in independent samples measured by different laboratories
and are infeasible in clinical application… …we found prognostic
signatures derived using the
relative genes (miRNAs) expression
rankings
within samples, rather than the absolute expression
values, are robust in
independent datasets from different
laboratories and platforms
.
Application Scenarios
【Ask a question】 DESeq and other methods detect differentially
expressed genes (DEGs) in
sub-groups of cancer samples
,
considering the
high heterogeneity
of lncRNA expression
among patients,
none have been used in detecting DE lncRNAs in
individual patients
.
【Hypothesis】The authors’ previous work found that the relative
expression rankings of genes (miRNAs) tend to be
highly stable
in specific normal
human tissues but
widely disturbed
in the corresponding cancer
tissues, and the reversal
relationship of rank between genes (miRNAs) expression level can be used
to identify DE genes (miRNAs) in individual patient. This time, we will
look at DE lncRNAs in individual patients in the same way
【Solution】In this paper, a method LncRIndiv (detect DE lncRNAs in
individual patients) is established, that is, a method of prognostic
model construction using gene-pair, that is, prognostic modeling through
pairs of genes.
For example, for genes A and B, the expression level of A > B is
set to 1, and the expression level of A < B is set to 0. Multiple
pairs of genes were screened out and turned into 0 and 1 forms for
prognostic model construction.
I’m going to take you through the repetition of this approach.
【Advantages】The model obtained based on sequencing is platform
independent, as long as the expression of single sample genes is
comparable. … due to experimental batch effects and platform
differences, the
score-based signatures
tend to produce
spurious risk classification in independent samples measured by
different laboratories and are infeasible in clinical application… … we
found prognostic signatures derived using the
relative genes
(miRNAs) expression rankings
within samples, rather than the
absolute expression values, are robust in
independent datasets
from different laboratories and platforms
.
环境设置
Environment settings
source("install_dependencies.R")
library(matlab)
library(EnvStats)
library(pheatmap)

Sys.setenv(LANGUAGE = "en") #显示英文报错信息 # error messages are displayed in English
options(stringsAsFactors = FALSE) #禁止chr转成factor # chr is not allowed to be converted to factor
自定义函数 Custom functions
display.progress = function (index, totalN, breakN=20) {
  if ( index %% ceiling(totalN/breakN)  ==0  ) {
    cat(paste(round(index*100/totalN), "% ", sep=""))
  }
}
输入文件
这里用的数据是原文的测试数据GSE27262，包括50例样本，25肿瘤和25正常。GEO数据下载和预处理方式可参考FigureYa203combat。
Input files
The data used here is the original test data GSE27262, including 50
samples, 25 tumors and 25 normal. For details about how to download and
preprocess GEO data, see FigureYa203combat.
# 加载样本信息
# Load sample information
Sinfo <- read.table("gse27262.sinfo.txt",sep = "\t",row.names = 1,check.names = F,stringsAsFactors = F,header = T)
# 提取肿瘤和正常样本
# Tumor and normal samples are extracted
tumsam <- rownames(Sinfo[which(substr(Sinfo$Title,30,31) == "T"),])
norsam <- rownames(Sinfo[which(substr(Sinfo$Title,30,31) == "N"),])

# 加载表达谱
# Load the expression spectrum
Expr <- read.table("gse27262.expr.txt",sep = "\t",row.names = 1,check.names = F,stringsAsFactors = F,header = T)
Expr$gene <- sapply(strsplit(rownames(Expr)," /// "), "[",1)
Expr <- as.data.frame(apply(Expr[,setdiff(colnames(Expr), "gene")], 2, function(x) tapply(x, INDEX=factor(Expr$gene), FUN=mean, na.rm=TRUE)))

# 加载注释文件，用于提取lncRNA
# Load the annotation file for lncRNA extraction
Ginfo <- read.table("overlapTable27.txt",sep = "\t",row.names = 1,check.names = F,stringsAsFactors = F,header = T)

# 提取lncRNA
# Extract lncRNA
Lids <- Ginfo[Ginfo$genetype %in% c("non_coding","3prime_overlapping_ncRNA","antisense_RNA","lincRNA","sense_intronic","sense_overlapping","macro_lncRNA","bidirectional_promoter_lncRNA"),]
Lids <- intersect(rownames(Expr),Lids$genename)
Expr <- Expr[Lids,]
使用gene-pair构建预后模型
第一步：表达谱编秩，然后选取在正常样本中秩序一致率达到95%的基因对，即lncRNA1
- lncRNA2方向一致（<0）的基因对出现在超过95%以上的正常样本中
Use gene-pair to build a prognostic model
Step 1: Expression profile ranking, and then select gene pairs with
95% order consistency rate in normal samples, that is, gene pairs with
the same direction (<0) of lncRNA1 - lncRNA2 appear in more than 95%
of normal samples
Step 1: The absolute expression profile of lncRNAs is transformed
into
rank profile
.
Stable lncRNA pairs
were defined as patterns of
rank, such as lncRNA-A < lncRNA-B, appearing in more than 95% of
normal samples (P = 6.26 × 10−23, binomial test, Fig. 1a).
# 表达谱编秩，transform absolute expression profile into rank profile
# Expression spectrum ranking,transform absolute expression profile into rank profile
expr.rank <- apply(Expr, 2, rank)

# 自定义函数，找出stable lncRNA pairs
# Customize the function to find stable lncRNA pairs
slec_stable_pair_nor <- function(expE,cutoff) { 
  
  gid  <- rownames(expE)
  exp  <- as.matrix(expE)
  len  <- length(gid)-1 
  end  <- length(gid)
  m    <- length(exp[1,]) 
  pair <- matrix(nrow=choose(length(gid),2),ncol=3) 
  j <- 1 
  for (i in 1:len) {
    RE=(exp[i*ones(len-i+1,1),]-exp[(i+1):end,]) < 0 
    if(i == len) {
      ratio <- sum(RE)/m
      pair[j,] <- c(rep(gid[i],end-i),gid[(i+1):end],ratio) 
    } else {
      ratio <- rowSums(RE)/m 
      pair[j:(j+length(RE[,1])-1),] <- c(rep(gid[i],end-i),gid[(i+1):end],ratio) 
      j <- j + length(RE[,1])
    }
  } 
  stable_pair_1 <- pair[pair[,3] >= cutoff,1:2] 
  stable_pair_2 <- pair[pair[,3] <= 1-cutoff,2:1] 
  stable_pair <- rbind.data.frame(stable_pair_1,stable_pair_2) 
  rownames(stable_pair) <- paste0(stable_pair$V1,"-",stable_pair$V2)
  return(list(pair = pair,
              stable_pair = stable_pair,
              stable_pair_1 = stable_pair_1,
              stable_pair_2 = stable_pair_2))
} 

# 找出stable lncRNA pairs in normal samples
# Find stable lncRNA pairs in normal samples
stablePairNorm <- slec_stable_pair_nor(expr.rank[,norsam],cutoff = 0.95)$stable_pair
write.table(stablePairNorm,"output_stable lncRNA pair in normal samples.txt",sep = "\t",row.names = T,col.names = NA,quote = F)
第二步：选取在肿瘤样本中显著相反的基因对
Step 2: Select gene pairs that are significantly opposite in the
tumor sample
Step 2:Take lncRNA-A as an example. According to the rules in Fig.
1a, there are five reversal pairs with lncRNA-A in cancer samples,
including partner lncRNAs lncRNA-B, lncRNA-C, lncRNA-D, lncRNA- E, and
lncRNA-F. **Only the partner lncRNAs that have the same dysregulation
directions as lncRNA-A in the lncRNA-A reversal pairs are retained.*
Here, the dysregulation directions indicated the expression of lncRNA-A
is up-regulated in the cancer group comparing with the normal group. In
Fig. 1b, the lncRNA-C is removed because of the down-regulation
trend.
这里构建了如原文图1a右下角表格里的频数矩阵，记录了上述稳定的基因对在肿瘤以及在正常样本中，lncRNA1
> lncRNA2 和 lncRNA1 < lncRNA2的数目。
Here, the frequency matrix in the table in the lower right corner of
Figure 1a is constructed to record the number of lncRNA1 > lncRNA2
and lncRNA1 < lncRNA2 in tumors and normal samples. The Fisher test
for the independence of the frequency matrix was performed in order to
obtain gene pairs that were significantly opposite in the tumor sample,
and to enrich lncRNA1 > lncRNA2 in the tumor sample.
对频数矩阵做独立性fisher检验，为了获取在肿瘤样本中方向显著相反的基因对，及在肿瘤样本中富集lncRNA1
> lncRNA2。
The independent Fisher test was performed on the frequency matrix to
obtain gene pairs that were significantly opposite in the direction in
the tumor sample, and to enrich lncRNA1 > lncRNA2 in the tumor
sample.
fdr.cutoff <- 0.1

outTab <- NULL
for (i in 1:nrow(stablePairNorm)) {
  display.progress(index = i, totalN = nrow(stablePairNorm))
  GP1 <- stablePairNorm[i,"V1"]
  GP2 <- stablePairNorm[i,"V2"]
  label <- rownames(stablePairNorm)[i]
  res <- data.frame(diff.tum = expr.rank[GP1,tumsam] - expr.rank[GP2,tumsam],
                    diff.nor = expr.rank[GP1,norsam] - expr.rank[GP2,norsam])

  # 计算当前基因对的失调方向（肿瘤 vs 正常）
  # Calculate the direction of the current gene pair out of regulation (tumor vs normal)
  avg1 <- mean(expr.rank[GP1,tumsam]) - mean(expr.rank[GP1,norsam])
  avg2 <- mean(expr.rank[GP2,tumsam]) - mean(expr.rank[GP2,norsam])
  
  res$tum.dirct <- factor(ifelse(res$diff.tum < 0,"a<b.T","a>b.T"),levels = c("a<b.T","a>b.T"))
  res$norm.dirct <- factor(ifelse(res$diff.nor < 0,"a<b.N","a>b.N"),levels = c("a<b.N","a>b.N"))
  
  # 构建矩阵（原文图1a的右下角表格）
  # Build the matrix (table in the lower right corner of Figure 1a in the original text)
  tmp <- matrix(c(as.numeric(table(res$norm.dirct)),as.numeric(table(res$tum.dirct))),
                nrow = 2,byrow = T,
                dimnames = list(c("Normal","Tumor"),c("a<b","a>b")))
  
  # 生成结果
  # Generate results
  outTab <- rbind.data.frame(outTab,
                             data.frame(V1 = GP1, # 当前基因对的第一个基因 # The first gene of the current gene pair
                                        V2 = GP2, # 当前基因对的第二个基因 # The second gene of the current gene pair
                                        avg1 = avg1, # 第一个基因在肿瘤vs正常里的秩水平 # The rank level of the first gene in tumor vs normal
                                        avg2 = avg2, # 第二个基因在肿瘤vs正常里的秩水平 # The rank level of the second gene in tumor vs. normal
                                        dirct = ifelse(avg1*avg2 > 0,"same","different"), # 若基因对的两个基因的失调方向一致则为same，否则为different # If the two genes of the gene pair are in the same direction of dysregulation, it is same, otherwise it is different
                                        altb.N = tmp[1,1],
                                        agtb.N = tmp[1,2],
                                        altb.T = tmp[2,1],
                                        agtb.T = tmp[2,2],
                                        p = fisher.test(tmp)$p.value, # fisher检验结果 # Fisher test results
                                        row.names = label,
                                        stringsAsFactors = F),
                             stringsAsFactors = F)
}
# 校正p值并选取在正常和肿瘤样本中有差异的基因对
# Correct the p-value and select the gene pairs that are different in normal and tumor samples
outTab$FDR <- p.adjust(outTab$p,method = "BH")
outSel <- outTab[which(outTab$FDR < fdr.cutoff),]
outSel <- outSel[which(outSel$dirct == "same"),]

# 保存到文件
# Save to file
write.table(outTab,"output_independency test of lncRNA pair between normal and tumor samples.txt",sep = "\t",row.names = T,col.names = NA,quote = F)
write.table(outSel,"output_significant lncRNA pair between normal and tumor samples.txt",sep = "\t",row.names = T,col.names = NA,quote = F)
第三步：计算lncRNA.A的所有partner在所有样本里的CV，升序排列取前3个表达最稳定的partner用来表征lncRNA.A
Step 3: Calculate the CVs of all partners of lncRNA.A in all
samples, and select the first 3 partners with the most stable expression
in ascending order to characterize lncRNA.A
Step 3:Then, we calculate the
coefficient of variation
(CV)
of rank across cancer and normal samples for each partner
lncRNA of lncRNA-A in the lncRNA-A reversal pairs (Fig. 1b).
We
hypothesize
that if the rank of partner lncRNA is approximately
constant across the cancer and normal samples, the reversal relationship
of lncRNA-A and partner lncRNA may occur because of the rank change of
lncRNA-A, which could be used as evidence to determine whether lncRNA-A
is differentially expressed in individual cancer samples. Then, the
partner lncRNAs of lncRNA-A are ranked by the CV in increasing order. If
there are more than 3 reversal pairs for lncRNA-A, the
top 3
reversal pairs
are retained; otherwise, all are included for
the following analysis. In Fig. 1b, the lncRNA-D, lncRNA-E and lncRNA-F
are the top three lncRNAs with the smallest CV and are included in
following analysis.
n.top <- 3 # 取top3个partner # Take the top 3 partners

outTab2 <- NULL
lncA <- unique(outSel$V1)
for (i in lncA) { # 循环每个lncRNA.A # Cycle each lncRNA.A
  tmp <- outSel[which(outSel$V1 == i),] # 取出所有pair # Extract all pairs
  resTab <- NULL
  for (j in tmp$V2) { # 循环每个可能的partner # Cycle through each possible partner
    expr <- expr.rank[j,]
    expr.cv <- cv(expr) # 计算CV # Calculate CV
    resTab <- rbind.data.frame(resTab,
                               data.frame(lncRNA.A = i,
                                          partner = j,
                                          cv = expr.cv,
                                          stringsAsFactors = F),
                               stringsAsFactors = Fa)
  }
  resTab <- resTab[order(resTab$cv,decreasing = F),,drop = F] # 升序排列 # Sort in ascending order
  if(nrow(resTab) >= n.top) { # 只取<=n.top个partner # Only < = n.top partners will be extracted
    resTab <- resTab[1:n.top,]
  } 
  outTab2 <- rbind.data.frame(outTab2,
                              resTab,
                              stringsAsFactors = F)
}
write.table(outTab2,"output_lncRNA partner with cv in all samples.txt",sep = "\t",row.names = F,col.names = T,quote = F)
第四步：检测差异lncRNA（若超过半数lncRNA.A >
partner，则该lncRNA.A在该样本中上调，记为1）
Step 4: Detect differential lncRNAs (if more than half of the
lncRNAs.A > partner, the lncRNA.A will be upregulated in the sample
and denoted as 1)
Step 4: In this example, the top 3 reversal lncRNA pairs (lncRNA-A
> lncRNA-D, lncRNA-A > lncRNA-E and lncRNA-A > lncRNA-F) are
used to determine whether lncRNA-A is differentially expressed in an
individual patient.
If more than half of the reversal lncRNA
pairs are detected in a patient
, we conclude that lncRNA-A is
differentially expressed in the patient (red human shape in Fig.
1b).
dysTab <- as.data.frame(matrix(NA,nrow = length(lncA),ncol = length(tumsam),byrow = T,
                 dimnames = list(lncA,tumsam)))

for (i in tumsam) { # 循环每个肿瘤样本 # Circulate each tumor sample
  for (j in lncA) { # 循环每个lncRNA.A # Cycle each lncRNA.A
    tmp <- outTab2[which(outTab2$lncRNA.A == j),] # 取出该lncRNA.A的对应partner # Extract the lncRNA.A's partner
    pos <- 0
    for (k in tmp$partner) { # 循环每个partner # Loop each partner
      if(expr.rank[j,i] - expr.rank[k,i] > 0) { # 判断lncRNA.A的表达是否大于partner的表达 # Determine whether the expression of lncRNA.A is greater than that of partner
        pos <- pos + 1 # 若大于则增加一次计数 # If it is greater than that, the count will be increased by one time
      } else {pos <- pos}
    }
    
    if(pos >= ceiling(0.5 * nrow(tmp))) { # 若计数超过半数的partner # If more than half of the partners are counted
      dysTab[j,i] <- 1 # 则该lncRNA.A在该样本i中为1 # then the lncRNA.A is 1 in the sample i
      } else {
      dysTab[j,i] <- 0 # 否则为0 # Otherwise it is 0
      }
  }
}

write.table(dysTab,"output_lncRNA dysregulation matrix in tumor samples.txt",sep = "\t",row.names = T,col.names = NA,quote = F)
开始画图
画个热图瞧一瞧
上面找到的差异基因在各个sample中的上下调情况。
Start drawing
Draw a heatmap and take a look
The up-down and down-regulation of the differentially generated genes
found above in each sample.
pheatmap(dysTab,
         border_color = NA,
         cluster_rows = T,
         cluster_cols = T,
         color = c("black","yellow"),
         show_colnames = T,
         show_rownames = F,
         legend_breaks = c(0,0.5,1),
         legend_labels = c("DN.Reg.","","UP.Reg."),
         filename = "lncRNA dysregulation heatmap.pdf")

save.image(file = "GP.RData")
gene-pair关系的展示
这些gene-pair的关系、CV值，以及上下调方向，可以画个网络图来展示，可参考
FigureYa199crosslink
。
或者用热图、散点图等方式展示基因表达的相关性和p value，Fig. 3
bc，可参考
https://mp.weixin.qq.com/s/D9wheY5QdnOh4JrjIc8-Cg
。
或者用散点图展示基因对在两组样本中的表达趋势，可参考
FigureYa96R2
Gene-pair relationship display
The relationship between these gene-pairs, CV values, and the
direction of upward and downward adjustments can be shown by drawing a
network diagram, which can be referred to ‘FigureYa199crosslink’.
Or use heat maps, scatter plots, etc. to show the correlation and p
value of gene expression, Fig. 3 bc, refer to
https://mp.weixin.qq.com/s/D9wheY5QdnOh4JrjIc8-Cg
。
Alternatively, a scatter plot can be used to show the expression
trend of gene pairs in two groups of samples, please refer to
‘FigureYa96R2’
gene-pair 作为诊断marker的效果（Performance evaluation）
生存分析，Fig. 2 abc，可参考
FigureYa1survivalCurve
高低风险组基因表达量分布，Fig. 2
de，可参考
FigureYa162boxViolin
Cox regression analyses，Table
2，可参考
FigureYa47HRtable
Effect of gene-pair as a diagnostic marker (Performance
evaluation)
Survival analysis, Fig. 2 abc, see ‘FigureYa1survivalCurve’
Gene expression distribution in the high and low risk groups, Fig. 2
de, see ‘FigureYa162boxViolin’
Cox regression analyses, Table 2, see ‘FigureYa47HRtable’
Session Info
sessionInfo()